- Deciphera Pharmaceuticals Announces Closing of Public Offering of Common Stock and Full Exercise of Underwriters' Option to Purchase Additional Shares
- Deciphera Pharmaceuticals Presents Results from ctDNA Analysis of INTRIGUE Phase 3 Clinical Study at the American Society of Clinical Oncology Plenary Series Session
- Deciphera Pharmaceuticals Announces Pricing of Public Offering of Common Stock
- Deciphera Pharmaceuticals Announces Proposed Public Offering of Common Stock
- Deciphera Pharmaceuticals Announces Planned 2023 Corporate Milestones to Support Continued Evolution to Multi-Product Company
- Deciphera Pharmaceuticals Announces Results from ctDNA Analysis from INTRIGUE Phase 3 Clinical Study Demonstrating Substantial Clinical Benefit of QINLOCK® in Second-Line GIST Patients with Mutations in KIT Exon 11 and 17/18 Only
- Deciphera Pharmaceuticals, Inc. to Present at the 41st Annual J.P. Morgan Healthcare Conference
- Deciphera Pharmaceuticals, Inc. to Present at the JMP Securities Hematology and Oncology Summit
- Deciphera Pharmaceuticals, Inc. to Participate in Upcoming Investor Conferences
- Deciphera Pharmaceuticals, Inc. Announces Third Quarter 2022 Financial Results
More ▼
Key statistics
As of last trade Deciphera Pharmaceuticals Inc (DCPH:NSQ) traded at 16.95, -25.55% below its 52-week high of 22.76, set on Jan 12, 2023.
52-week range
Markit short selling activity
Open | 17.01 |
---|---|
High | 17.27 |
Low | 16.82 |
Bid | 16.91 |
Offer | 16.96 |
Previous close | 17.31 |
Average volume | 1.13m |
---|---|
Shares outstanding | 74.37m |
Free float | 49.11m |
P/E (TTM) | -- |
Market cap | 1.29bn USD |
EPS (TTM) | -3.46 USD |
Data delayed at least 15 minutes, as of Jan 30 2023 16:00 GMT.
More ▼